Evidence map›Paper›PMID 22508712›Full record

ArticleThe Journal of clinical endocrinology and metabolism2012

Sleeping parathyroid tumor: rapid hyperfunction after removal of the dominant tumor.

Sahzene Yavuz, William F Simonds, Lee S Weinstein, Michael T Collins, Electron Kebebew, Naris Nilubol, Giao Q Phan, Steven K Libutti, Alan T Remaley, Manuel Van Deventer and 1 more

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Intraoperative parathyroid hormone assay-cutting the Gordian knot.Indian journal of endocrinology and metabolism · 2014
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Sahzene YavuzDiabetes, Endocrine and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. sahzene.yavuz@nih.gov
William F Simonds
Lee S Weinstein
Michael T Collins
Electron Kebebew
Naris Nilubol
Giao Q Phan
Steven K Libutti
Alan T Remaley
Manuel Van Deventer
Stephen J Marx
National Cancer Institute · USNational Institute of Diabetes and Digestive and Kidney Diseases · USNational Institutes of Health Clinical Center · USAlbert Einstein College of Medicine · USNational Institute of Dental and Craniofacial Research · US

Funding

Skeletal Disorders and Mineral Homeostasis SectionZIADE000649 · NIDCR · NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH · PI COLLINS, MICHAEL · 2009 to 2025
$32.8M
The NIH Inter-Institute Training Program in Endocrinology, Diabetes & MetabolismZIEDK075100 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI MUNIYAPPA, RANGANATH · 2009 to 2025
$18.0M
Hyperparathyroidism-- Etiology, Diagnosis And TreatmentZIADK043006 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JHA, SMITA · 2011 to 2025
$8.9M
Clinical Investigation of FIHP, Parathyroid Cancer & the HPT-JT SyndromeZIADK043012 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI SIMONDS, WILLIAM F · 2009 to 2025
$4.3M
Pathophysiology Of Multiple Endocrine Neoplasia Type 1ZIEDK043009 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI MARX, STEPHEN · 2009 to 2012
$1.0M
MEN1 as a Tumor Suppressor GeneZIEDK043321 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI MARX, STEPHEN · 2009 to 2012
$1.0M
Hyperparathyroidism- Location of tumor and treatment after failed surgeryZIEDK043323 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI MARX, STEPHEN · 2009 to 2012
$1.0M
Pathophysiology Of Multiple Endocrine Neoplasia Type 1ZIADK043009 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI MARX, STEPHEN · 2013 to 2015
$495k
Hyperparathyroidism- Location of tumor and treatment after failed surgeryZIADK043323 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI MARX, STEPHEN · 2013 to 2015
$495k
Intramural NIH HHS
6 · The paper itself

Abstract

contextDue to frequent multiplicity of tumors in multiple endocrine neoplasia type 1, it may be difficult to decide when to stop a parathyroid exploration. A fall of intraoperative serum PTH by a certain percentage during parathyroid surgery is often used as one criterion for ending the operation.

resultsWe report two patients with primary hyperparathyroidism due to multiple endocrine neoplasia type 1 who had their first parathyroidectomy at the National Institutes of Health. In both cases, two and a half glands were removed, an extensive search was done for an occult parathyroid tumor, and intraoperative PTH decreased markedly to the lower limits of normal, suggesting a successful operation. Despite this, both patients became hypercalcemic within 3 d after the operation and showed persistent primary hyperparathyroidism. Detailed findings suggest the following course: chronic hypercalcemia had caused near total suppression of PTH secretion by an undiscovered parathyroid tumor (sleeping parathyroid tumor). When the hypercalcemia decreased after surgery due to the removal of the dominant parathyroid tumor(s), the abnormal yet previously suppressed tumor rapidly began to oversecrete PTH and thus caused postoperative hypercalcemia.

conclusionsEven a fall of the intraoperative PTH to the lower limits of the normal range cannot guarantee that removal of all parathyroid tumors has been complete in cases with multiple tumors. These findings likely reflect strikingly differing PTH secretory functions among distinct tumors in the same patient, with hypercalcemia at least from a dominant tumor suppressing PTH secretion by one or more other parathyroid tumors.

Indexed as

AdolescentFalse Positive ReactionsHumansHypercalcemiaHyperparathyroidism, PrimaryMaleMultiple Endocrine Neoplasia Type 1ParathyroidectomyParathyroid HormoneParathyroid NeoplasmsPostoperative ComplicationsYoung AdultParathyroid Hormone

Identifiers

PMID22508712
PMCPMC3387414
OpenAlexW1999556816

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.